Phase II trial of quadrivalent split influenza vaccine in healthy children aged 6-35 months

Phase 2 trial of influenza virus vaccine, quadrivalent, split virus in influenza (3 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Positive conversion rate of HI antibodies for all influenza strains in the whole population 30 days after full immunization, Geometric mean titer of HI antibodies for all influenza strains in the whole population 30 days after full immunization and 3 more. Planned start Oct 2022; status: not yet recruiting.